OppenheimerFunds’s Ligand Pharmaceuticals LGND Stock Holding History

OppenheimerFunds’s Portfolio LGND Stock Details LGND Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q1	$40.9M	Sell	521,980 -188,809	-27%	-$14.3M	0.05%	355
2018 Q4	$60.2M	Buy	710,789 +119,144	+20%	+$12.7M	0.09%	233
2018 Q3	$101M	Buy	591,645 +76,321	+15%	+$11.5M	0.12%	190
2018 Q2	$66.6M	Buy	515,324 +42,601	+9%	+$4.75M	0.08%	273
2018 Q1	$48.7M	Buy	472,723 +67,227	+17%	+$6.65M	0.06%	324
2017 Q4	$34.6M	Buy	405,496 +172,450	+74%	+$14.9M	0.04%	421
2017 Q3	$19.8M	Buy	233,046 +62,387	+37%	+$4.94M	0.02%	568
2017 Q2	$12.9M	Buy	170,659 +21,287	+14%	+$1.49M	0.02%	688
2017 Q1	$9.86M	Sell	149,372 -39,699	-21%	-$2.61M	0.01%	763
2016 Q4	$12M	Sell	189,071 -104,929	-36%	-$6.62M	0.02%	719
2016 Q3	$18.7M	Buy	+294,000	New	+$21.6M	0.02%	591

Other funds holding LGND

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return

CCMLC

Cardinal Capital Management LLC (Connecticut) Greenwich, Connecticut $365M AUM 18.32% 1-Year Est. Return

Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return

CCA

Conestoga Capital Advisors Wayne, Pennsylvania $5.01B AUM 6.26% 1-Year Est. Return

Manulife (Manufacturers Life Insurance) Canada, Ontario, Canada $116B AUM 26.37% 1-Year Est. Return

OppenheimerFunds's LGND Position: Q1 2019 in Review

OppenheimerFunds reduced its Ligand Pharmaceuticals (LGND) stake by 27% in Q1 2019, selling an estimated $14.3M and leaving 521,980 shares worth $40.9M. The position accounts for 0.05% of the portfolio, ranked #355.

OppenheimerFunds first reported a position in LGND in Q3 2016 and has held it in 11 quarters since. The position peaked at $101M in Q3 2018. 330 funds tracked by Wall St. Rank hold LGND as of Q1 2019.

OppenheimerFunds held 521,980 shares of Ligand Pharmaceuticals worth $40.9M as of Q1 2019.
OppenheimerFunds sold 188,809 Ligand Pharmaceuticals shares in Q1 2019, an estimated $14.3M.
Ligand Pharmaceuticals made up 0.05% of OppenheimerFunds's portfolio in Q1 2019, its #355 holding.
OppenheimerFunds first reported a position in Ligand Pharmaceuticals in Q3 2016 and has held it in 11 quarters since.
OppenheimerFunds's Ligand Pharmaceuticals position peaked at $101M in Q3 2018.
330 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q1 2019.

Based on OppenheimerFunds's 13F filing for Q1 2019, filed 13 May 2019.